Literature DB >> 33440255

Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study.

Mirna Chehade1, Amol P Kamboj2, Dan Atkins3, Lauren T Gehman2.   

Abstract

BACKGROUND: Eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) is characterized by persistent symptoms and elevated eosinophils in the gastrointestinal tract. Limited disease awareness and lack of diagnostic guidelines suggest that patients may remain undiagnosed or endure diagnostic delay.
OBJECTIVE: To characterize the path to diagnosis for patients with EG/EoD in a representative population.
METHODS: In this observational cohort study, 4108 eligible patients diagnosed with EG/EoD between 2008 and 2018 were identified in an administrative claims database in the United States. Patient medical claim history was analyzed to describe events related to diagnosis.
RESULTS: Mean year from symptom presentation to diagnosis of EG/EoD was 3.6; factors contributing to diagnostic delay included delayed gastroenterologist referral, delayed esophagogastroduodenoscopy (EGD), and lack of biopsy collection and/or histopathologic evaluation. Missed diagnosis on index EGD occurred in 38.2% of patients, resulting in a mean increase of 1.6 years in time to diagnosis versus patients diagnosed on index EGD. Patients presented with nonspecific symptoms and 44.3% were diagnosed with another gastrointestinal condition before EG/EoD diagnosis. Independent predictors of >2-year diagnostic delay included adult age; prior diagnosis of irritable bowel syndrome, functional dyspepsia, or gastric/peptic ulcer; use of other procedures such as colonoscopy; presence of edema; and history of certain allergic diseases.
CONCLUSIONS: This study found that patients with EG/EoD experienced an average of 3.6 years between initial symptom presentation and diagnosis and revealed several factors contributing to diagnostic delay. We hope that these findings, together with heightened awareness and standardization of diagnostic guidelines, will improve the diagnostic journey of patients with EG/EoD.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Eosinophilic enteritis; Eosinophilic esophagitis; Eosinophilic gastroenteritis; Eosinophilic gastrointestinal disease

Year:  2021        PMID: 33440255     DOI: 10.1016/j.jaip.2020.12.054

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  7 in total

1.  International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature.

Authors:  Evan S Dellon; Nirmala Gonsalves; J Pablo Abonia; Jeffrey A Alexander; Nicoleta C Arva; Dan Atkins; Stephen E Attwood; Marcus K H Auth; Dominique D Bailey; Luc Biederman; Carine Blanchard; Peter A Bonis; Paroma Bose; Albert J Bredenoord; Joy W Chang; Mirna Chehade; Margaret H Collins; Carlo Di Lorenzo; Jorge Amil Dias; Ranjan Dohil; Christophe Dupont; Gary W Falk; Cristina T Ferreira; Adam T Fox; Robert M Genta; Thomas Greuter; Sandeep K Gupta; Ikuo Hirano; Girish S Hiremath; Jennifer L Horsley-Silva; Shunji Ishihara; Norihisa Ishimura; Elizabeth T Jensen; Carolina Gutiérrez-Junquera; David A Katzka; Paneez Khoury; Yoshikazu Kinoshita; Kara L Kliewer; Sibylle Koletzko; John Leung; Chris A Liacouras; Alfredo J Lucendo; Lisa J Martin; Emily C McGowan; Calies Menard-Katcher; David C Metz; Talya L Miller; Fouad J Moawad; Amanda B Muir; Vincent A Mukkada; Simon Murch; Quan M Nhu; Ichiro Nomura; Samuel Nurko; Yoshikazu Ohtsuka; Salvatore Oliva; Rok Orel; Alexandra Papadopoulou; Dhyanesh A Patel; Robert D Pesek; Kathryn A Peterson; Hamish Philpott; Philip E Putnam; Joel E Richter; Rachel Rosen; Melanie A Ruffner; Ekaterina Safroneeva; Philipp Schreiner; Alain Schoepfer; Shauna R Schroeder; Neil Shah; Rhonda F Souza; Stuart J Spechler; Jonathan M Spergel; Alex Straumann; Nicholas J Talley; Nikhil Thapar; Yvan Vandenplas; Rajitha D Venkatesh; Mario C Vieira; Ulrike von Arnim; Marjorie M Walker; Joshua B Wechsler; Barry K Wershil; Benjamin L Wright; Yoshiyuki Yamada; Guang-Yu Yang; Noam Zevit; Marc E Rothenberg; Glenn T Furuta; Seema S Aceves
Journal:  Clin Gastroenterol Hepatol       Date:  2022-02-16       Impact factor: 13.576

2.  Eosinophilic Gastrointestinal Diseases Beyond Eosinophilic Esophagitis.

Authors:  Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2022-01-25       Impact factor: 12.045

3.  Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field.

Authors:  Marc E Rothenberg; Shawna K B Hottinger; Nirmala Gonsalves; Glenn T Furuta; Margaret H Collins; Nicholas J Talley; Kathryn Peterson; Calies Menard-Katcher; Macie Smith; Ikuo Hirano; Robert M Genta; Mirna Chehade; Sandeep K Gupta; Jonathan M Spergel; Seema S Aceves; Evan S Dellon
Journal:  J Allergy Clin Immunol       Date:  2021-12-22       Impact factor: 10.793

4.  Psychiatric Comorbidities Are Highly Prevalent in Nonesophageal Eosinophilic Gastrointestinal Diseases.

Authors:  Craig C Reed; Corey J Ketchem; Talya L Miller; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2021-05-28       Impact factor: 11.382

5.  Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents.

Authors:  Calvin N Ho; Sean O'Quinn; Julie Bailey; Oren Meyers; Ashley F Slagle; Evan S Dellon; Catherine Datto
Journal:  Orphanet J Rare Dis       Date:  2021-11-24       Impact factor: 4.123

6.  Improving Care in Eosinophil-Associated Diseases: A Charter.

Authors:  David J Jackson; Praveen Akuthota; Rebeca Andradas; Albert J Bredenoord; Amanda Cordell; Sarah Gray; Joyce Kullman; Sameer K Mathur; Ian Pavord; Florence Roufosse; Christian Rubio; Irena Clisson Rusek; Dagmar Simon; Mary Jo Strobel; Tonya Winders
Journal:  Adv Ther       Date:  2022-04-30       Impact factor: 4.070

Review 7.  Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.

Authors:  Simon Dagenais; Leo Russo; Ann Madsen; Jen Webster; Lauren Becnel
Journal:  Clin Pharmacol Ther       Date:  2021-11-28       Impact factor: 6.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.